Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells.
The leukocyte integrin Mac-1 (CD11b/CD18) and the urokinase receptor (uPAR, CD87) mediate complementary functions in myelomonocytic cells. Both receptors promote degradation of fibrin(ogen) and also confer adhesive properties on cells because Mac-1 and uPAR bind fibrin and vitronectin, respectively. Staining of lung biopsy specimens from patients with acute lung injury indicated that fibrin and vitronectin colocalize at exudative sites in which macrophages bearing these receptors accumulate. Because of the parallel roles and physical proximity of Mac-1 and uPAR, the capacity of these receptors to functionally interact was explored. Induction of Mac-1 and uPAR expression on monocytic cell lines by transforming growth factor- beta 1 and 1.25-(OH)2 vitamin D3 conferred urokinase and uPAR-dependent adhesion to vitronectin, which was further promoted by engagement of Mac-1. Vitronectin attachment promoted subsequent Mac-1-mediated fibrinogen degradation threefold to fourfold. In contrast, enhancement of uPAR occupancy by exogenous urokinase or receptor binding fragments thereof inhibited Mac-1 function. Addition of urokinase progressively inhibited Mac-1-mediated fibrinogen binding and degradation (maximal inhibition, 91% +/- 14% and 72% +/- 15%, respectively). Saturation of uPAR with urokinase also inhibited binding of the procoagulant Mac-1 ligand, Factor X. These inhibitory effects of uPAR were reproduced in fresh monocytes, cultured monocytic cells, and in Chinese hamster ovary (CHO) cells transfected with both human Mac-1 and human uPAR. These data show that the procoagulant and fibrinolytic potential of monocytic cells is co-ordinately regulated by ligand binding to both Mac-1 and uPAR and identify uPAR as a regulator of integrin function. Vitronectin-enhanced fibrin(ogen) turnover by Mac-1 may operate as a salvage pathway in the setting of urokinase and plasmin inhibitors to promote clearance of the provisional matrix and subsequent healing.
Simon
D I
DI
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Rao
N K
NK
Xu
H
H
Wei
Y
Y
Majdic
O
O
Ronne
E
E
Kobzik
L
L
Chapman
H A
HA
D000818:Animals; D001777:Blood Coagulation / Q000502:physiology; D018821:CD18 Antigens / Q000235:genetics / Q000502:physiology*; D016466:CHO Cells; D002117:Calcitriol / Q000494:pharmacology; D002448:Cell Adhesion; D006224:Cricetinae; D005170:Factor X / Q000378:metabolism; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000473:pathology; D008168:Lung / Q000378:metabolism; D055370:Lung Injury; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology; D046911:Macromolecular Substances; D016177:Macrophage-1 Antigen / Q000235:genetics / Q000502:physiology*; D008264:Macrophages / Q000502:physiology; D009000:Monocytes / Q000737:chemistry / Q000502:physiology*; D009363:Neoplasm Proteins / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000235:genetics / Q000502:physiology*; D055293:Receptors, Urokinase Plasminogen Activator; D011994:Recombinant Proteins / Q000378:metabolism / Q000494:pharmacology; D014162:Transfection; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology; D019096:Vitronectin / Q000378:metabolism
D018821:CD18 Antigens; D046911:Macromolecular Substances; D016177:Macrophage-1 Antigen; D009363:Neoplasm Proteins; C524898:PLAUR protein, human; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D019096:Vitronectin; D005170:Factor X; D005337:Fibrin; D005340:Fibrinogen; D014568:Urokinase-Type Plasminogen Activator; D002117:Calcitriol